ASCO 2021 | Unanswered questions in CAR-T therapies
Jennifer Brudno
• 27 May 2021
Jennifer Brudno, MD, National Cancer Institute, Bethesda, MD, explores unanswered questions regarding chimeric antigen receptor (CAR) T-cell therapies in hematologic malignancies. Commercially available CAR T-cell therapies such as idecabtagene vicleucel and axicabtagene ciloleucel were tested in pre-treated patients in clinical trials, opening up the possibility of using CAR T-cell therapy in earlier lines of treatment. Dr Brudno suggests that administering CAR T-cell therapies earlier may increase efficacy due to patients being exposed less to prior chemotherapy and consequently having a more robust immune system. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
